A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...
We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...
The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...
